‘A completely new level of insight’: Iqvia unveils patient engagement solution

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/fizkes)
(Image: Getty/fizkes)

Related tags: IQVIA, patient engagement, Belong.Life

Iqvia’s Orchestrated Patient Engagement solution, powered by Belong.Life, delivers ‘hyper-personalized’ content to engage and support patients, providing insights that will benefit patients, life sciences companies, and the health care system, says CEO.

“We believe that engaging patients effectively demands domain expertise and disruptive technology,”​ Andrew Ploszay, PhD, vice president, digital strategy, global technology solutions, Iqvia, told us.

Powered by Belong.Life, Iqvia’s Orchestrated Patient Engagement (OPE) is a cloud-based software as a service (SaaS) solution that, according to the company, helps ‘close the gap’ between life sciences companies and patients.

Belong.Life Co-Founder and CEO Eliran Malki said the development of the platform has been the company’s primary focus over the last few months after closed a $14m Series B investment round​ in July of this year.

The aim is to improve patient engagement by generating “a completely new level of insight that will benefit patients, life sciences companies, and the wider health care system,” ​he said, noting the company’s excitement about the launch and continued work with Iqvia, which led the investment round.

Earlier this year, Belong.Life unveiled its patient engagement platform (PEP), which provides patients, payers, providers, and life science companies with configurable patient engagement tools, navigation, and management services.

The platform builds on the company’s mobile app, “Belong – Beating Cancer Together,” a social network for cancer patients, caregivers, and health care professionals.

“Our experience with the Belong.Life Beating Cancer Together app has provided us a wealth of knowledge regarding how to successfully apply AI and machine learning to deliver hyper-personalized content with which patients actually want to engage,”​ said Malki.

“Anyone who has tried to build or use a patient engagement platform understands the challenges surrounding engaging patients. In order to generate enough data points to produce actionable insights you need patients to really connect to the platform,”​ he added.

Speaking to the launch of OPE, Malki said, “The solution can deliver a full 360-degree view of a patient’s treatments and needs alongside active support.”

Iqvia OPE will be available in the US in the fourth quarter of 2019.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more